How has ImmunityBio, Inc.'s cash and cash equivalents, end of period changed year-over-year?

ImmunityBio, Inc.'s cash and cash equivalents, end of period increased by 237.7% year-over-year, from $61.14M to $206.47M.

What is the long-term trend for ImmunityBio, Inc.'s cash and cash equivalents, end of period?

Over 5 years (2020 to 2025), ImmunityBio, Inc.'s cash and cash equivalents, end of period has grown at a 20.6% compound annual growth rate (CAGR), from $35.09M to $89.43M.

ImmunityBio, Inc. IBRX Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

Eli LillyLLY

——

Other financials

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s cash and cash equivalents, end of period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s cash and cash equivalents, end of period?: ImmunityBio, Inc. (IBRX) reported cash and cash equivalents, end of period of $206.47M in Q1 2026.
How has ImmunityBio, Inc.'s cash and cash equivalents, end of period changed year-over-year?: ImmunityBio, Inc.'s cash and cash equivalents, end of period increased by 237.7% year-over-year, from $61.14M to $206.47M.
What is the long-term trend for ImmunityBio, Inc.'s cash and cash equivalents, end of period?: Over 5 years (2020 to 2025), ImmunityBio, Inc.'s cash and cash equivalents, end of period has grown at a 20.6% compound annual growth rate (CAGR), from $35.09M to $89.43M.